PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC.

Kaufman, Bar; Taha, Tarek; Abramov, Orli; Zohar, Yaniv; Mhameed, Kamel; Cohen, Ofir; Porgador, Angel; Elkabets, Moshe; Billan, Salem

Kaufman, Bar; Taha, Tarek; Abramov, Orli; Zohar, Yaniv; Mhameed, Kamel; Cohen, Ofir; Porgador, Angel; Elkabets, Moshe; Billan, Salem.

Afiliación

Kaufman B; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.
Taha T; The Joseph Fishman Oncology Center, Rambam Health Care Campus, Haifa, Affiliated to the Rappaport Faculty of Medicine, Israel Institute of Technology-Technion, Haifa, 3109601, Israel.
Abramov O; Oncology institute, Tzafon Medical Center, Poriya affiliated with Azrieli Faculty of Medicine, Bar Ilan University, Ramat Gan, Israel.
Zohar Y; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.
Mhameed K; Institute of Pathology, Rambam Health Care Campus, Haifa, 3109601, Israel.
Cohen O; The Joseph Fishman Oncology Center, Rambam Health Care Campus, Haifa, Affiliated to the Rappaport Faculty of Medicine, Israel Institute of Technology-Technion, Haifa, 3109601, Israel.
Porgador A; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.
Elkabets M; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel. angel@bgu.ac.il.
Billan S; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel. moshee@bgu.ac.il.

NPJ Precis Oncol ; 8(1): 126, 2024 Jun 03.

Article en En | MEDLINE | ID: mdl-38830971

ABSTRACT

ABSTRACT

Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands' functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NPJ Precis Oncol Año: 2024 Tipo del documento: Article País de afiliación: Israel

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google